OpenScience.ink

3 weeks ago • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

How well combined treatments work for people with chronic kidney disease and type 2 diabetes using real-world dataComparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data.

🎖️ Top 10% JournalArticle

3 weeks ago • Nutrients

Why Fully Reporting Diet Matters in Studies of GLP-1 Receptor Agonist TreatmentsDietary Intake as an Undermeasured Potential Mediator: The Ethical Case for Complete and Transparent Dietary Reporting in GLP-1 Receptor Agonist Trials.

🎖️ Top 10% JournalArticle

3 weeks ago • Pharmaceuticals (Basel, Switzerland)

Incretin-based treatments and their links to testosterone and hormone responses in men with low testosteroneEffects of Incretin-Based Therapies on Testosterone Levels and Incretin Response in Men with Hypogonadism: A Systematic Literature Review Following PRISMA 2020 Guidelines.

📖 Top 20% JournalArticle

3 weeks ago • Cancers

Use of GLP-1 Receptor Drugs in Cancer Survivors: Challenges and OpportunitiesGLP-1 Receptor Agonist Use in Cancer Survivors-Challenges and Opportunities: A Narrative Review.

🎖️ Top 10% JournalArticle

3 weeks ago • The Journal of clinical endocrinology and metabolism

Semaglutide versus Weight-Loss Surgery on Noninvasive Signs of Liver Fat and Scarring in Obesity with MASLDEffects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD.

🥉 Top 5% JournalArticle

3 weeks ago • Nutrients

How Belief in Social Media Stories About Weight-Loss Drugs Relates to Willingness to Use Combined Obesity Treatments and SupportPerceived Credibility of Social Media Narratives About GLP-1 Receptor Agonists and Acceptance of Integrated Obesity Care: Implications for Nutrition and Lifestyle Support.

🎖️ Top 10% JournalArticle

3 weeks ago • Cardiovascular drugs and therapy

Ongoing Inflammation Risk in Heart Failure with Preserved Pumping: Using Multiple Organs to Track, Select Patients, and Evaluate Treatments Over TimeCandidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal.

Article

3 weeks ago • Obesity pillars

Use of GLP-1 and GLP-1/GIP Medicines and Their Reported Effects in People with Lipedema from a Large Online SurveyGLP-1 and GLP-1/GIP receptor agonist medication use and self-reported outcomes in individuals with lipedema: Results from a large online survey.

📖 Top 20% JournalArticle

3 weeks ago • Diabetes, obesity & metabolism

Link Between GLP-1 Receptor Agonist Drugs and Diabetic Eye DiseaseAssociation of GLP1-Receptor Agonists With Diabetic Retinopathy.

Article

3 weeks ago • Trends in pharmacological sciences

Identifying how GLP1R signaling favors different pathwaysDe-Nterm-ining GLP1R signaling bias.

🥈 Top 2% JournalArticle

3 weeks ago • Cardiovascular diabetology

Disease-changing diabetes drugs: linking the SIMPLE method to stopping disease earlyDisease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.

🥈 Top 2% JournalArticle

3 weeks ago • Medicina (Kaunas, Lithuania)

Using Medicine and Metabolic Weight-Loss Surgery Together in Endometrial Cancer TreatmentBeyond Weight Loss: A Comprehensive Review of Integrated Pharmacotherapy and Metabolic Bariatric Surgery in Endometrial Cancer Care.

📖 Top 30% JournalArticle

← prevpage 11 of 14next →

Latest GLP-1 Therapies Research Papers